Other parameters significantly linked to local or distant recurrence risk were: mastitis at presentation, high tumor grade, HER2 negativity, larger residual enhancing tumor diameter on post-therapeutic MRI (Fig. 3). This evidence concerns the gene ERBB2 and mastitis.